Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Blood cells returned to stem cell state by Johns Hopkins researchers

Johns Hopkins scientists have developed a reliable method to turn the clock back on blood cells, restoring them to a primitive stem cell state from which they can then develop into any other type of cell in the body.

22 Aug 2012

Abortion issue gets spotlight in swing states

Meanwhile, as the GOP prepares to include tough anti-abortion positions in its party platform, the Associated Press notes that voters in the presidential race will get a stark choice on social issues, including access to birth control and abortion rights.

22 Aug 2012

SSEA4+ marker helps identify and isolate precursors of insulin-producing pancreatic cells

For the millions of people worldwide with type 1 diabetes who cannot produce sufficient insulin, the potential to transplant insulin-producing cells could offer hope for a long-term cure. The discovery of a marker to help identify and isolate stem cells that can develop into insulin-producing cells in the pancreas would be a critical step forward and is described in an article in BioResearch Open Access, a new bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc.

22 Aug 2012

Study on sea lamprey may indicate how potentially deleterious genes can be controlled

Research on a unique vertebrate called the sea lamprey shows that more than a thousand genes are shed during its early development.

22 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

Mof protein plays a key role in epigenetics of stem cells

How do stem cells preserve their ability to become any type of cell in the body? And how do they "decide" to give up that magical state and start specializing? If researchers could answer these questions, our ability to harness stem cells to treat disease could explode. Now, a University of Michigan Medical School team has published a key discovery that could help that goal become reality.

22 Aug 2012

Stem-cell therapy holds promise for postinjury arthritis prevention

A novel stem-cell treatment may hold the key to treating osteoarthritis triggered by joint injury, suggest results from an animal study.

21 Aug 2012

Lack of certain gene occurs in almost 28% of breast cancers

More than one out of every four cases of breast cancer is associated with a specific, missing gene - a finding that could have significant implications for chemotherapy treatments, according a recent study by Cornell University researchers.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Implanted cells' therapeutic properties depend on their shape

Tissue implants made of cells grown on a sponge-like scaffold have been shown in clinical trials to help heal arteries scarred by atherosclerosis and other vascular diseases. However, it has been unclear why some implants work better than others.

16 Aug 2012

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121.

15 Aug 2012

Targeting elevated HLX gene expression may treat acute myeloid leukemia

Scientists at Albert Einstein College of Medicine of Yeshiva University have made a discovery involving mice and humans that could mean that people with acute myeloid leukemia (AML), a rare and usually fatal cancer, are a step closer to new treatment options. Their study results were published online today in Cancer Cell.

14 Aug 2012

Pathway describes how alpha hydroxyl acids cause skin exfoliation

A team of investigators from UC Davis and Peking University have discovered a mechanism that may explain how alpha hydroxyl acids (AHAs) -- the key ingredient in cosmetic chemical peels and wrinkle-reducing creams -- work to enhance skin appearance. An understanding of the underlying process may lead to better cosmetic formulations as well as have medical applications.

14 Aug 2012

Verastem second quarter net loss increases to $6.8 million

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended June 30, 2012, and also commented on certain corporate accomplishments and plans.

13 Aug 2012

Promising stem cell therapy may prevent osteoarthritis after joint injury

Duke researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

10 Aug 2012

Nanofibers and VEGF hold promise for cardiovascular repair

A National Cheng Kung University research team has made a breakthrough in the regeneration of new blood vessels in cardiovascular therapy by using nanofibers and vascular endothelial growth factor.

10 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

New research hopes to uncover mystery behind breast cancer metastasis

If detected early, most cases of breast cancer are curable. But if the tumour has metastasized - or spread to a site outside of the breast - cure rates decline. A team of researchers from Lawson Health Research Institute and Western University have received $449,733 from the Canadian Breast Cancer Foundation - Ontario Region to study a rare subpopulation of tumour cells called cancer stem cells (CSCs) in hopes of uncovering the mystery behind metastasis.

8 Aug 2012